Shanghai Henlius Biotech, Inc. (2696.HK)
- Previous Close
37.850 - Open
37.950 - Bid 38.400 x --
- Ask 38.450 x --
- Day's Range
37.600 - 38.650 - 52 Week Range
15.200 - 39.200 - Volume
410,700 - Avg. Volume
1,649,061 - Market Cap (intraday)
20.843B - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
23.82 - EPS (TTM)
1.610 - Earnings Date Mar 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
48.30
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma, and limited-stage small cell lung cancer; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, and HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania. The company was founded in 2010 and is headquartered in Shanghai, China.
www.henlius.comRecent News: 2696.HK
View More
Performance Overview: 2696.HK
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2696.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2696.HK
View MoreValuation Measures
Market Cap
20.57B
Enterprise Value
23.63B
Trailing P/E
23.55
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.38
Price/Book (mrq)
6.41
Enterprise Value/Revenue
3.88
Enterprise Value/EBITDA
16.52
Financial Highlights
Profitability and Income Statement
Profit Margin
14.33%
Return on Assets (ttm)
5.28%
Return on Equity (ttm)
31.52%
Revenue (ttm)
5.72B
Net Income Avi to Common (ttm)
820.47M
Diluted EPS (ttm)
1.610
Balance Sheet and Cash Flow
Total Cash (mrq)
813.73M
Total Debt/Equity (mrq)
121.06%
Levered Free Cash Flow (ttm)
176.66M